Reports that scientists have developed the world’s first vaccine against the mosquito-borne virus, dengue fever. (Credit: Caribbean360 / Bigstock)
LONDON, England, Friday July 18, 2014 – With most of the Caribbean and about half the world’s population at risk of contracting dengue fever, reports that scientists have developed the world’s first vaccine against the mosquito-borne virus seen to work in large-scale trials comes as good news.
Research published in Britain’s Lancet medical journal indicates that over 50 percent of children who are given the vaccine are protected against the disease.
Results are reportedly even more impressive on severe forms of the disease, in which the vaccine reduces the number of people requiring hospitalisation and prevents 80 percent of cases of potentially deadly dengue haemorrhagic fever.
Click here to receive free news bulletins via email from Caribbean360. (View sample)
Yet while experts describe the study as promising, they insist that vaccines with greater effectiveness are crucial.
Meanwhile, in this largest late-stage trial of a vaccine to date, researchers from five centres across Asia treated 6,000 children aged between two and 14 years.
At the end of two years, some 56 percent of the children were seen to have protection against the virus.
The vaccine reportedly worked best for children with certain subtypes of the virus and those with previous exposure.
There are currently no treatments to prevent dengue fever, an illness characterised by intense joint pain, high fever and severe headaches that affects more than one million people a year.
Sanofi-Pasteur, the company funding the current research, plans to apply for approval once the results of its second trial across the Caribbean and Latin America have been analysed.
View the original article here
Promising vaccine against dengue developed
